-transparent.png){kind=logo}
HA1077 is a newly synthesized vasodilator with unique intracellular calcium antagonistic action. In this study, its effect on the growth of vascular smooth muscle cells (VSMC) stimulated by fetal calf serum was examined. Both the proliferation and [3H]thymidine incorporation into DNA of the growth-arrested VSMC was dose-dependently inhibited by HA1077. The expression of a proto-oncogene, c-fos, which reached the maximum 30 min after addition of serum, was similarly inhibited by this agent in a dose-dependent manner. Thus, HA1077 is expected to be a useful vasodilator agent capable of suppressing the growth of VSMC which is thought to be an important underlying mechanism of atherosclerosis or restenosis after angioplasty.
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
April 1990,
Cell regulation,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
October 1988,
FEBS letters,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
June 1996,
Hypertension (Dallas, Tex. : 1979),
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
August 1991,
Clinical and experimental pharmacology & physiology,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
March 1998,
The Journal of clinical investigation,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
December 1993,
Atherosclerosis,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
January 1988,
IARC scientific publications,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
January 1999,
Zhongguo yao li xue bao = Acta pharmacologica Sinica,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
August 1999,
Biochemical and biophysical research communications,
K Sase, and
Y Yui, and
R Hattori, and
M Shirotani, and
C Kawai, and
S Sasayama
January 2000,
American journal of physiology. Cell physiology,
